AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Tezspire (tezepelumab by Year
Tezspire (tezepelumab — direct product sales) — Europe YoY CER (%) (%)
AstraZeneca Tezspire (tezepelumab: 83.0% in FY2025.
Latest, FY2025
83.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 6-K FY2025Q4 Earnings Release
Where the FY2025 figure comes from
“|| Tezspire | 458 | 85 | 80 | - | - | 40 | n/m | n/m | 297 | 90 | 83 | 121 | 51 | 51”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tezspire (tezepelumab — direct product sales) — Europe YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Tezspire (tezepelumab (%), annual FY2025–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tezspire-eu-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.